These investment cases provide structured, evidence-based justifications for prioritizing investment in promising vaccine products.
They aim to catalyze alignment across global health stakeholders with different perspectives, including funders, manufacturers, policymakers, and implementers, by combining robust demand projections, market viability assessments, delivery feasibility, and financing strategies.




